Shareholders in British drugmaker GlaxoSmithKline (GSK.L) have approved a planned deal with Switzerland’s Novartis (NOVN.VX), which will see the two pharmaceutical groups trade more than $20 billion (12.7 billion pounds) of assets.
{iframe}http://uk.reuters.com/article/2014/12/18/uk-gsk-m-a-novartis-idUKKBN0JW1HY20141218{/iframe}